They found that 6.4 percent of men on finasteride had high-grade tumors , compared with 5.1 percent taking a placebo .
About 18 percent of men taking finasteride developed prostate cancer , compared with 24 percent on placebo .
At 12 months , there was still a difference between the groups , but it was not considered significant .